

Carbapenem resistant *Acinetobacter baumannii* versus MRSA isolates in ICU in Clinical Center Skopje

Katja Popovska¹, Milka Zdravkovska², Milena Petrovska¹, Azis Pollozhani³

¹Institute of Microbiology and parasitology, Faculty of Medicine, University “Ss Cyril and Methodius”, Skopje, Republic of Macedonia

²Faculty of Medical Sciences, University “Goce Delchev”, Stip, Republic of Macedonia

³Institute for Public Health of the Republic of Macedonia, Skopje, Republic of Macedonia

Email address:

katja.popovska@t-home.mk (K. Popovska)

To cite this article:

Katja Popovska, Milka Zdravkovska, Milena Petrovska, Azis Pollozhani. Carbapenem Resistant *Acinetobacter Baumannii* Versus MRSA Isolates in ICU in Clinical Center Skopje. *European Journal of Preventive Medicine*. Vol. 2, No. 2, 2014, pp. 20-24.

doi: 10.11648/j.ejpm.20140202.11

Abstract: Background: *Acinetobacter baumannii* is often referred to as the “Gram-negative methicillin-resistant *Staphylococcus aureus*”, because it is frequently resistant to antibiotics. Clonal outbreaks of carbapenem-resistant and OXA-23–producing *A. baumannii* have been reported worldwide. Aim: The goal of this study was to promote the phenomenon of disbalance in endemic hospital ECO system which included increase of carbapenemase-resistant *Acinetobacter baumannii* on account of reduction of MRSA rate in surgical ICU and it’s clonal relatedness as well as the specific precautions. Material nad Methods: Computer database from 1994 – 2012 from surgical ICU patients in the Clinical Center Skopje was used as basic material for this study. Comparative study indicated 2007/8 as a break point period in which almost a twofold decrease of MRSA rates (from over 80% to 45%) versus increased rates of *Acinetobacter baumannii* (from 29% to 40%) was observed. In 2011 the very first eight strains of carbapenem resistant (resistant to imipenem and meropenem) *A. baumannii*, were observed. Disc diffusion and VITEK were used for antibiotic susceptibility testing. Resultes: Three distinct strains were detected by PFGE and were designated as UKIM01AC-1 (5 strains), UKIM01AC-2 (two strains) and 642/2 (one strain). UKIM01AC-1 representatives were PCR positive for bla (OXA-23-like), in addition to the bla (OXA- 51-like) gene which is intrinsic in *Acinetobacter baumannii*. All isolated strains belonged to European clone II lineage. Conclusion: This clone dispersed very fast in 2012 and achieved the rate of 61.9%. This implicated changes in infection control precautions.

Keywords: *Acinetobacter*; Carbapenem Resistance, Clonal Distribution, Endemic ECO System

1. Background

Acinetobacter baumannii is often referred to as the “Gram-negative methicillin-resistant *Staphylococcus aureus*”, because it is frequently resistant to antibiotics. [1,2,3]

The epidemiologies of the two microbial species are very different and therefore, it is questionable whether the same control measures can be applied to the two pathogens. MRSA is primarily spread from person-to-person, whereas *Acinetobacter* infections often have an environmental source or reservoir. Allen and Green concluded that widespread aerial dissemination of *Acinetobacter* spp. occurred and this partly contributed to the environmental reservoir.

Referring to Allen and Green’s study, Das et al. [4] hypothesised that heavily contaminated bed curtains, when moved would promote the airborne spread of *Acinetobacter*

spp. Weernink et al. [5] investigated the airborne dispersal of *Acinetobacter baumannii* from patient’s pillows. Using settle plates they found aerial dissemination from feather pillows, but not from synthetic pillows.

Numerous investigators have demonstrated the relative ease with which the clinical environment can become contaminated with pathogenic *Acinetobacter* species.

Dissemination by airborne or other routes can seed environmental reservoirs which either can start [6] or prolong outbreaks [7,8]. In institutions where outbreaks occur in ICUs, a common contaminated object in the environment can often be identified as the source. In contrast, in other hospitals, where epidemic infections have become endemic, the clinical and microbiological epidemiology of

these infections often remains obscure. Allen and Green [4] were the first to suggest airborne dissemination of *Acinetobacter*-carrying particles. Investigating an outbreak of multiply-antibiotic resistant *Acinetobacter anitratus* in an ICU, a medical ward and three neurosurgical wards, they cultured the outbreak organism from 16 of 82 settle plates. Interestingly, all the positive plates were located within 3m of the colonised patients.

There are studies showing the geographically widespread occurrence of multidrug-resistant *A. baumannii* strains, which suggested a clonal relatedness of these strains. [9, 10] Three international *A. baumannii* clones associated with multidrug resistance (European clones I, II, and III) have been reported).

Clonal outbreaks of carbapenem-resistant and OXA-23-producing *A. baumannii* have been reported in many countries, such as Bulgaria, People's Republic of China, Brazil, Iraq, Afghanistan, Spain [9,10,11].

2. Aim of the Study

The goal of this study was to promote the phenomenon of disbalance in endemic hospital ECO system which included increase of carbapenemase-resistant *Acinetobacter baumannii* on account of reduction of MRSA rate in surgical ICU, by long-term monitoring, and the track whether disseminated strains of *Acinetobacter* were relevant. The final goal of this investigation was to promote specific precautions in order to minimise the acquisition and spread of these emerging infections that are difficult to treat.

3. Methodology

Comparative monitoring from database has indicated that there is a connection among emerging isolation of MDR *Acinetobacter baumannii* versus declination of MRSA isolates, both originating from surgical ICU patients in a long period of time.

2007/8 has been indicated as a break point period in which there was decrease of MRSA rates (from over 80% to 45%) versus increased rates of *Acinetobacter baumannii* isolation (from 29% to 40%) [Fig 1].




Figure 1. *Acinetobacter* isolation in ICU in the period of 1991/1994, 2006/2007 and 2010/2012 year

Table 1. Significance of isolation ratio for *Acinetobacter* isolates (1991/1994, 2006/2007 and 2010/2012 year)

Period	Student – t test of proportions
1991 / 1994 – 2006 / 2007	p = 0,0020 (Sign.)
1991 / 1994 – 2010 / 2012	p = 0,0018 (Sign.)
2006 / 2007 – 2010 / 2012	p = 0,7613 (N.Sign.)

Acinetobacter baumannii is an important nosocomial pathogen in this Unit. In the period from 1991-1994 the rate of isolation was 29% (N=363). It significantly arised in the period from 2006-2007 to 40% (N=355) and reflect this level in the next 5 years. On the other hand, MRSA became an important isolate in ICU in 1997 with over 80% rates sustaining percentage during the next decade, until 2007 when it was almost twice reduced. [Fig 2].




Fig 2. MRSA isolation in ICU in the period 1994-2008

Amikacin used to be a drug of choice in treatment of *Acinetobacter baumannii* infections during this long period of time, which has resulted in significant increasing (p=0,0017) the resistance to this antibiotic in the period from 2005-2007 [Fig 3].




Figure 3. Resistance of *Acinetobacter* isolates to amikacin and introduction of carbapenems (imipenem)

That is why carbapenems, firstly imipenem and later on meropenem, were involved in therapy in the early 2000s.

3.1. Design of the Study

Antibiotic resistance among *Acinetobacter baumannii* has been observed in 3 periods of time: early period 1990 – 2004, middle period 2005-2007 and recent period 2010-2012.

Strains of *Acinetobacter baumannii* originated from

entubated patients in the surgical ICU. They were identified by classical microbiological procedure and confirmed by automatic VITEK technique). Susceptibility patterns to β -lactam antimicrobial drugs were determined by using a standard disk diffusion method according to published standards. Then strains of interest were determined by the agar dilution method, according to established NCCLS and confirmed by automatic VITEK test. Observation included 3 routinely used antibiotics, amikacin, imipenem and meropenem, since the observed strains were MDR.

Student's t-test of proportion was the epidemiological tool used in order to monitor the changes in resistance to carbapenems, from year to year, in the middle period and in the recent period of observation.

Eight strains of *Acinetobacter baumannii* were recognized to be resistant to both routinely used carbapenems (imipenem and meropenem) in the recent period, that was not the case with all other strains isolated ever before.

Clonal relatedness of these strains was assessed by pulsed-field gel electrophoresis (PFGE) and multilocus sequence typing in Health Protection Agency London by kindly collaboration with Prof Dr T.Pitt and Dr.Jane Turtone.[1,12]

Presence of the *bla*_{OXA-23} gene was screened by PCR using specific primers (OXA-23-A 5'-GGAATTCCATGAATAAATATTTTACTTGC-3' and OXA-23-B 5'-CGGGATCCCGTTAAATAATATTCAGGTC-3'). Further PCR detection of the clones was performed in Institute of microbiology Skopje.

4. Results

4.1. *Acinetobacter Baumannii* Ratio in Surgical ICU in the 21 Year Period

The rates of *Acinetobacter baumannii* isolation in the 21 year period of observation in the surgical ICU, have shown a significant increase in the middle period (2006/7) with 40% (0,0018) rate of isolation. This trend of isolation has been observed in next the "recent period" (38,5%), (2010-2012). [Fig 1].

The rate of isolation of MRSA as predominant pathogen in CARIC with 80% ratio has been found over ten year-period, until 2007/8, when it suddenly decreased to 40% [Fig 2].

4.2. Antibiotic Susceptibility

Comparison of antibiotic resistance to amikacin among the three investigated periods showed a significant ramp from 30% to 80% ($p=0.00001$) in the middle period (2006/2007) and almost complete (97%) resistance in the "recent period" (2010-2012) among 208 isolates of *Acinetobacter*. [Tab 1]

These data coincide with the introduction of imipenem in the treatment of surgical ICU patients, and registration the first imipenem-resistant strains (10%) in the same period [Fig 3].

Ramps of resistance to imipenem from year to year, pointed a significant increase of imipenem-resistance in 2007. [Fig 4].




Figure 4. Dynamic of the resistance of *Acinetobacter* spp. to imipenem in the middle period – 2005/2007

Trend of spreading resistance to imipenem reached 73% ($p=0,00001$) in the "recent period" (2010-12) [Fig 5].




Fig 5. Imipenem and meropenem resistance of *Acinetobacter baumannii* in 2010/2012

According to Student's t-test of proportion comparing 2011 and 2010, there was a significant ($p = 0,0003$) elevation of resistance to imipenem, as well as to meropenem ($p=0,00001$) (from 33% to 60% to Imipenem, and from 19,5% to 66% for meropenem).

This trend was also observed in the first semester of 2012, but it was still not significant in 2011 for imipenem ($p=0,2010$) as well as for meropenem ($p=0,2598$) [Fig 5].

According to the data provided by the supplying service in the Surgery clinic, the use of relevant antibiotics in 2012 versus 2011 displayed 59% increase for meropenem (370amp. vs 180) and 40 % decrease for imipenem (1010 amp. vs 2465 amp).

4.3. Molecular Analysis of Resistant Strains

Carbapenem-resistant *Acinetobacter baumannii* strains (resistant to both carbapenems) were isolated in 2011 by PFGE analysis, and were similar in dendograms. Five strains had identical dendogram and were designated as UKIMAC1, 2 other similar strains designated as UKIMAC2 and only one unique strain [Tab 2].

Tab 2. PCR recognition of carbapenemase genes

Designation of test strains	Bla(OXA 58 like)	Bla(OXA 23 like)	Bla(OXA 51 like)	Bla (OXA 40 like)
UKIM01 AC-1 (N=5)	negative	positive	positive	negative
UKIM01AC-2	negative	negative	positive	negative
642/2 unique	negative	negative	positive	negative

PFGE analysis and random amplified polymorphic DNA (RAPD) generated by arbitrarily primed polymerase chain reaction of these eight isolates indicated 2 closely related genotypes (2 clones).

The OXA-23-producing isolates belonged to all genotypes. The presence of MDR OXA-23-producing *A. baumannii* in ICU has emphasized the need to control the use of carbapenems.

5. Discussion

Continuous monitoring is the basic tool in control of HAI, because it provides plenty of data about what happens in hospital ECO system, including appearance of MDR strains among endemic isolates and according to Rampell, changes in balance in hospital ECO system.

By long-term monitoring *Acinetobacter baumannii* has been confirmed as an important nosocomial pathogen in CARIC in the period 1991-1994, but it was increased in the period of 2007/8 - 2012, on account of MRSA. Similar finding for the same period of time, were referred from the investigation in some other countries such as Brazil or Taiwan [17,18].

The comparative study indicated significant changes in EKO system in 2007/8 in investigated ICU. MRSA rates were almost double reduced and on the other side, rates of *Acinetobacter baumannii* significantly increased. [13]

Considering many differences in epidemiological characteristics of these two microorganisms, it was assumed that global or local conditions in the unit have been changed and/ it can be connected with the global changes in the climate [19,20]. Therefore *Acinetobacter* isolates became an important problem in this Unit, especially when carbapenem resistance was noticed in 2011 among eight strains which had been nonsusceptible to all other antibiotics tested by the agar dilution method.

All isolates of *Acinetobacter* were nonsusceptible to all of the antibiotics tested by the agar dilution method except amikacin until 2007 when resistance achieved 80%. After that imipenem was involved as alternative antibiotic therapy. In the next 5 years resistance among acinetobacters was spread very fast, almost completely to aminoglycoside (93%) and very high to imipenem (73%). Since therapeutic choice of *Acinetobacter* infections was small, meropenem was involved uncontrolled in therapeutic routine practice [Tab3].

Table 3. Use of carbapenems in ICU for period 2011-2012

	Ampulas used in 2011	Ampulas used in 2012
meropenem	180	370
imipenem	2465	1010
gentamicin	270	380

This led to sudden development of meropenem-resistance. Among eight carbapenem resistant *Acinetobacter baumannii* tested representatives three distinct strains were detected by PFGE. Five of them could possibly belong to the same source – type UKIM01AC-1 and another two were

connected - UKIM01AC 2. All representatives of UKIM01AC-1 were PCR positive for bla (OXA-23-like), in addition to the bla (OXA-51-like) gene, which was intrinsic in *Acinetobacter baumannii*. All isolated strains belonged to European clone II lineage. [14], although there are data for *A.baumannii* isolates positive for bla (OXA-23-like) on american continent [17]. This clone dispersed very fast in 2012 and achieved the rate of 61,9% (N=84).

6. Conclusion

Carbapenem resistant *Acinetobacter baumannii* (European clone II, became significant pathogen in CARIC, replacing MRSA which was predominant cause of infections in over ten years period of time. This MDR clone expressed big capacity for intra/inter-hospital dissemination of the clone, which was confirmed by literature data and was due to irrational antibiotic usage in CARIC.

The new situation in this hospital ECO system indicated revision of hospital control strategies and applying new specific precautions. It was recommended: strong artificial control of air humidity, negative pressure in the critical room, proper care for bed-linen, replacement cotton with synthetic pillow, proper laundry of bed-linen, removal of mattress (once being Acinetobacter-positive). Strong monitoring should be conducted over effect of recommended precautions for the following period of time.

References

- [1] Silvia Munoz-Price and Robert A. Weinstein (2008) *Acinetobacter* Infection N Engl J Med 1271-1281.
- [2] Bou G, Cervero G, Angeles Dominguez M, Quereda C, Martinez-Beltran J.(2000) Characterization of a nosocomial outbreak caused by multiresistant *Acinetobacter baumannii* strain with a carbapenem-hydrolyzing enzyme: high-level carbapenem resistance in *A. baumannii* is not due solely to the presence of β -lactamases. J Clin Microbiol. 3299–3305.
- [3] Ethan Rubinstein and Itzhak Levy (1999) *Acinetobacter* spp. and other non-fermentative pathogens causing nosocomial bacteremias Clin Microbiol Infect 2S29-2S32
- [4] Allen KD, Green HT (1987) Hospital outbreak of multi-resistant *Acinetobacter anitratus*: an airborne mode of spread? J Hosp Infect 110–119.
- [5] Wernick, A (1995). Pillows, an unexpected source of acinetobacter. Journal of Hospital 189-199
- [6] Raffaele Zarrilli, Margherita Crispino, Maria Bagattini, Elena Barretta, Anna Di Popolo Maria Triassi and Paolo Villari (2004) Molecular Epidemiology of Sequential Outbreaks of *Acinetobacter baumannii* in an Intensive Care Unit Shows the Emergence of Carbapenem Resistance; J. Clin. Microbiol 946-953
- [7] Tankovic J, Legrand P, De Gaintes G, Cheminea V, Brun Buisson, Duval (1994) J.Characterization of a hospital outbreak of imipenem resistant *Acinetobacter baumannii* by phenotypic and genotypic typing methods. J Clin Microbiol 2677–2681.

- [8] Lolans K, Rice TW, Munoz-Price LS, Quinn JP (2006) Multicity outbreak of carbapenem-resistant *Acinetobacter baumannii* isolates producing the carbapenemase OXA-40. *Antimicrob Agents Chemother* 2941-2945
- [9] Wen-Shyand Hsieh, Nai-Yu Wang, Jou-An Feng, Li Chuan Weng and Hsueh Hsia Wu (2012) Types and Prevalence of Carbapenem-Resistant *Acinetobacter calcoaceticus*-*Acinetobacter baumannii* complex in Northern Taiwan. *J Clin Microbiol* 2982–2986.
- [10] Chaline S. Antonio, Patricia R. Neves, Micheli Medeiros and Elsa M. Mamizuka (2011) High prevalence of Carbapenem-Resistant *Acinetobacter baumannii* Carrying the blaOXA-143 Gene in Brazilian Hospitals. 1322-1233.
- [11] Rodriguez-Bano J, Cisneros JM, Fernandez-Cuenca F (2004) Clinical features and epidemiology of *Acinetobacter baumannii* colonization and infection in Spanish hospitals. *Infect Control Hosp Epidemiol* 819–824
- [12] Turton, J. F.(2006) The role of ISAbal in expression of OXA carbapenemase genes in *Acinetobacter baumannii*. *FEMS Microbiol. Lett.* 258:72-77.
- [13] Turton, J. F (2006) Identification of *Acinetobacter baumannii* by detection of the bla_{OXA-51}-like carbapenemase gene intrinsic to this species. *J. Clin. Microbiol* 2974-2976.
- [14] Evans B.A., Hamouda A., Amyes U.K (2013) The rise of carbapenem-resistant *Acinetobacter baumannii*. University of Manchester, Manchester, UK, 223-38.
- [15] Paul G Higgins^{1*}, Cathrin Dammhayn¹, Meredith Hackel² and Harald Seifert¹. (2009) Global spread of carbapenem-resistant *Acinetobacter baumannii*. *J Antimicrob Chemother* 1091-1093
- [16] Rea, E. Upshur, R. (2001). Semmelweis revisited: the ethics of infection prevention among health care workers. *Canadian Medical Association Journal* 1447-1448.
- [17] Charline S. Antonio, Patricia R. Neves, Micheli Medeiros and Elsa M. Mamizuka (2010). High prevalence of carbapenem-resistant *Acinetobacter baumannii* carrying the bla OXA-143 gene in Brazilian Hospitals. *Antimicrob Agent Chemoter* 1322-1323
- [18] Wen-Sen-ShyangHsieh, Nai-Yu Wang, Jou-An Feng. Types and prevalence of carbapenem-resistant *Acinetobacter calcoaceticus*-*Acinetobacter baumannii* complex in Northern Taiwan (published before print 2013) *Antimicrob Agent Chemoter* doi.10.1128/AAC.0079-13
- [19] Retalliau HF, Hightower AW, Dixon RE, Allen JR (1979) *Acinetobacter calcoaceticus*: a nosocomial pathogen with an unusual seasonal pattern. *J Infect Dis* 371-375.
- [20] McDonald LC, Banerjee S, Jarvis WR (1999) NNIS System. Seasonal variation of *Acinetobacter* spp. Infections reported to the National Nosocomial Infections Surveillance (NNIS) System: 1987–1996 [abstract no 55]. *Infect Control Hosp Epidemiol* 1133-1137